Hoffmann-la Roche Inc.

Meiji Seika Pharma Co., Ltd.

Fedora Pharmaceuticals Inc.

F. Hoffmann-la Roche Ag

Michael Kammerer

Urs Schwitter

Andrew William Thomas

Stefan Hildbrand

Olaf Grassmann

Nicole Wyttenbach

Pascal Dott

Joachim Manns

Fritz Bliss

Frédéric Ran

Dieu Nguyen

Florence Tixeront

John F Lang

Robert Carr

Mark L Hodges

William J Lawrimore Iii

The present invention relates to crystalline forms of a diazabicyclooctane derivative represented by Compound I, the process for producing the same and methods for using the same: 

Crystalline forms of diazabicyclooctane derivatives and production process thereof

The present invention relates to a process for producing crystalline and amorphous forms of a diazabicyclooctane derivative represented by Compound (I) and methods for producing the same. 

Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof

Co-crystals of Formula I compounds and their pharmaceutical compositions are novel therapeutics for the treatment of diseases, such as human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection and cancer. The co-crystal are more stable to oxidation and aqueous degradation, have a better pharmacokinetic profile and superior biological activity than the corresponding tosylate salt form of Formula I compound.

Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same

The instant invention relates to novel solid forms of the compound of formula (I) as well as solvates, inclusion complexes with other suitable compounds, processes for their manufacture, pharmaceutical compositions containing these solid forms, and their use as pharmaceuticals.

Solid forms

Growing community of inventors

Basel, Switzerland

Michael Kammerer